On November 3, 2026 Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, reported an upcoming poster presentation of first-in-human clinical data from a Phase 1 study of NG-348 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2026, being held from November 4–8, in Phoenix, Arizona.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NG-348 is an intravenously delivered oncolytic immunotherapy designed to drive intratumoral expression of two membrane-bound proteins that provide key signals for T cell activation: anti-CD3 single-chain variable fragment (scFv) and CD80. Tumor-cell surface expression of these molecules triggers antigen independent T-cell activation within the tumor microenvironment (TME), enabling direct tumor cell killing. By combining direct T cell engagement with oncolysis, NG-348 stimulates a robust anti-tumor response locally within the TME while also offering the potential to overcome immunotherapy resistance. The Phase 1 study assessed the safety, tolerability and preliminary anti-tumor effects of NG-348 monotherapy in patients with metastatic or advanced epithelial tumors refractory to standard therapies.
Poster Presentation Details:
Title: Phase 1 first-in-human study of NG-348 – an oncolytic adenovirus expressing CD80 and anti-CD3 scFv in patients with advanced epithelial tumors
Abstract: #497
Date and Time: November 6, 2026, 10 a.m. – 2 p.m. and 5 p.m. – 7 p.m. MT
Location: Phoenix Convention Center, North Exhibition Halls 4–6
(Press release, Akamis Bio, NOV 3, 2026, View Source [SID1234674115])